The beneficial human gut microbe Faecalibacterium prausnitzii is a ‘probiotic of the future’ since it produces high amounts of butyrate and anti-inflammatory compounds. However, this bacterium is highly oxygen-senstive, making it notoriously difficult to cultivate and preserve. This has so far precluded its clinical application in the treatment of patients with inflammatory bowel diseases. The present studies were therefore aimed at developing a strategy to keep F. prausnitzii alive at ambient air. Our previous research showed that F. prausnitzii can survive in moderately oxygenized environments like the gut mucosa by transfer of electrons to oxygen. For this purpose, the bacterium exploits extracellular antioxidants, such as riboflavin and cysteine, that are abundantly present in the gut. We therefore tested to what extent these antioxidants can sustain the viability of F. prausnitzii at ambient air. The present results show that cysteine can facilitate the survival of F. prausnitzii upon exposure to air, and that this effect is significantly enhanced the by addition of riboflavin and the cryoprotectant inulin. The highly oxygen-sensitive gut bacterium F. prausnitzii can be kept alive at ambient air for 24 h when formulated with the antioxidants cysteine and riboflavin plus the cryoprotectant inulin. Improved formulations were obtained by addition of the bulking agents corn starch and wheat bran. Our present findings pave the way towards the biomedical exploitation of F. prausnitzii in redox-based therapeutics for treatment of dysbiosis-related inflammatory disorders of the human gut.
References
[1]
Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, et al. (2012) Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment. Pharmacol. Ther 35: 828–838.
[2]
Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, et al. (2012) Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150: 470–480.
[3]
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, et al. (2012) Host-gut microbiota metabolic interactions. Science 336: 1262–1267.
[4]
Tremaroli V, Backhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature 489: 242–249.
[5]
Kayama H, Takeda K (2012) Regulation of intestinal homeostasis by innate and adaptive immunity. Int. Immunol 24: 673–680.
[6]
Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M (2012) The impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol 12: 728–734.
[7]
Butterworth AD, Thomas AG, Akobeng AK (2008) Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst. Rev 3: CD006634.
[8]
Toh ZQ, Anzela A, Tang ML, Licciardi PV (2012) Probiotic therapy as a novel approach for allergic disease. Front. Pharmacol 3: 171.
[9]
Videlock EJ, Cremonini F (2012) Probiotics for antibiotic-associated diarrhea. JAMA 308 : 665; author reply 665–6.
[10]
Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, et al. (2011) Recommendations for probiotic use-2011 update. J. Clin. Gastroenterol 45 SupplS168–71.
[11]
Vyas U, Ranganathan N (2012) Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract 2012: 872716.
[12]
Fuller R (1989) Probiotics in man and animals. J. Appl. Bacteriol 66: 365–378.
[13]
Goldin BR (1998) Health benefits of probiotics. Br. J. Nutr 80: S203–7.
[14]
Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, et al. (2009) Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br. J. Nutr 101: 541–550.
[15]
Gibson GR, Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr 125: 1401–1412.
[16]
Gibson GR, Beatty ER, Wang X, Cummings JH (1995) Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108: 975–982.
[17]
Kolida S, Gibson GR (2011) Synbiotics in health and disease. Annu. Rev. Food Sci. Technol. 2: 373–393, 2011.
[18]
Cummings JH (1981) Short chain fatty acids in the human colon. Gut 22: 763–779.
[19]
Mortensen PB, Clausen MR (1996) Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand. J. Gastroenterol. Suppl. 216: 132–148.
[20]
Hague A, Singh B, Paraskeva C (1997) Butyrate acts as a survival factor for colonic epithelial cells: further fuel for the in vivo versus in vitro debate. Gastroenterology 112: 1036–1040.
[21]
Sakata T (1987) Stimulatory effect of short-chain fatty acids on epithelial cell proliferation in the rat intestine: a possible explanation for trophic effects of fermentable fibre, gut microbes and luminal trophic factors. Br. J. Nutr 58: 95–103.
[22]
Shimotoyodome A, Meguro S, Hase T, Tokimitsu I, Sakata T (2000) Decreased colonic mucus in rats with loperamide-induced constipation. Comp. Biochem. Physiol. A. Mol. Integr. Physiol 126: 203–212.
[23]
Hold GL, Schwiertz A, Aminov RI, Blaut M, Flint HJ (2003) Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Appl. Environ. Microbio.l 69: 4320–4324.
[24]
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A 105: 16731–16736.
[25]
Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, et al. (2013) Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol 16: 255–61.
[26]
Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ (2002) Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int. J. Syst. Evol. Microbiol 52: 2141–2146.
[27]
Morgan CA, Herman N, White PA, Vesey G (2006) Preservation of micro-organisms by drying; a review. J. Microbiol. Methods 66: 183–193.
[28]
Miyamoto-Shinohara Y, Imaizumi T, Sukenobe J, Murakami Y, Kawamura S, et al. (2000) Survival rate of microbes after freeze-drying and long-term storage. Cryobiology 41: 251–255.
[29]
Bozoglu TF, Ozilgen M, Bakir U (1987) Survival kinetics of lactic acid starter cultures during and after freeze drying. Enzyme Microbiology Technology 9: 531–537.
[30]
Hubalek Z (2003) Protectants used in the cryopreservation of microorganisms. Cryobiology 46: 205–229.
[31]
Savini M, Cecchini C, Verdenelli MC, Silvi S, Orpianesi C, et al. (2010) Pilot-scale production and viability analysis of freeze-dried probiotic bacteria using different protective agents. Nutrients 2: 330–339.
[32]
Jedrzejczak-Krzepkowska M, Bielecki S (2011) Bifidobacteria and inulin-type fructans which stimulate their growth. Postepy. Biochem 57: 392–400.
[33]
de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A, et al. (2007) Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur. J. Pharm. Sci 32: 33–44.
[34]
Neyrinck AM, Van Hee VF, Piront N, De Backer F, Toussaint O, et al. (2012) Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr. Diabetes 2: e28.
[35]
Neyrinck AM, Possemiers S, Druart C, Van de Wiele T, De Backer F, et al. (2011) Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. PLoS One 6: e20944.
[36]
Ganzle MG, Follador R (2012) Metabolism of oligosaccharides and starch in lactobacilli: a review. Front. Microbiol. 3: 340.
[37]
Ross RP, Desmond C, Fitzgerald GF, Stanton C (2005) Overcoming the technological hurdles in the development of probiotic foods. J. Appl. Microbiol 98: 1410–1417.
[38]
Khan MT, Duncan SH, Stams AJ, van Dijl JM, Flint HJ, et al. (2012) The gut anaerobe Faecalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. ISME J 6: 1578–1585.
[39]
van Drooge DJ, Hinrichs WL, Dickhoff BH, Elli MN, Visser MR, et al. (2005) Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur. J. Pharm. Sci 26: 231–240.
[40]
Backhed F (2012) Host responses to the human microbiome. Nutr. Rev 70 Suppl 1S14–7.
[41]
Paturi G, Nyanhanda T, Butts CA, Herath TD, Monro JA, et al. (2012) Effects of potato fiber and potato-resistant starch on biomarkers of colonic health in rats fed diets containing red meat. J. Food Sci 77: H216–23.
[42]
Tachon S, Zhou J, Keenan M, Martin R, Marco ML (2013) The intestinal microbiota in aged mice is modulated by dietary resistant starch and correlated with improvements in host responses. FEMS Microbiol. Ecol 83: 299–309.
[43]
Ze X, Duncan SH, Louis P, Flint HJ (2012) Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J., 2012.
[44]
Kim CJ, Kovacs-Nolan J, Yang C, Archbold T, Fan MZ, et al. (2009) L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim. Biophys. Acta 1790: 1161–1169.
[45]
Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis 15: 1183–1189.
